 MIAMI, July 12, 2021 GLOBE NEWSWIRE -- OPKO Health, Inc. NASDAQ: OPK today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation CAMP4 for the development, manufacture and commercialization of therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA. AntagoNATs are oligonucleotide compounds that target non-coding natural antisense transcripts leading to an upregulation of a desired functional protein. CAMP4 has prioritized OPKOs lead AntagoNAT compound to progress into clinical trials for the treatment of Dravet syndrome. 